Literature DB >> 17826411

Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?

Helen Y How1, John R Barton, Niki B Istwan, Debbie J Rhea, Gary J Stanziano.   

Abstract

OBJECTIVE: The purpose of this study was to determine effectiveness of 17 alpha-hydroxyprogesterone caproate (17 P) prophylaxis by gestational age (GA) at 17 P initiation. STUDY
DESIGN: Singleton gestations with > or = 1 preterm birth (PTB) treated with 17 P prophylaxis for recurrent preterm birth before 27 weeks were identified from a data base. Data were stratified by GA at 17 P initiation (16-20.9 [n = 599] weeks and 21-26.9 [n = 307] weeks) and number of PTB (1, 2, > 2). Outcome variables were PTB at < 37, < 35, and < 32 weeks.
RESULTS: No significant differences were found in gestational age at delivery or rates of recurrent PTB < 37, < 35, and < 32 weeks between those women initiating 17 P at 16-20.9 weeks or 21-26.9 weeks, or when stratified by number of prior preterm deliveries.
CONCLUSION: Initiation of 17 P prophylaxis at 21-26.9 weeks is as effective as initiation at 16-20.9 weeks of gestation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17826411     DOI: 10.1016/j.ajog.2007.07.013

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

Review 1.  What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.

Authors:  Steve N Caritis; Maisa N Feghali; William A Grobman; Dwight J Rouse
Journal:  Semin Perinatol       Date:  2016-04-19       Impact factor: 3.300

2.  Propensity score matching for treatment delay effects with observational survival data.

Authors:  Erinn M Hade; Giovanni Nattino; Heather A Frey; Bo Lu
Journal:  Stat Methods Med Res       Date:  2019-10-01       Impact factor: 3.021

3.  Progesterone supplementation and the prevention of preterm birth.

Authors:  Errol R Norwitz; Aaron B Caughey
Journal:  Rev Obstet Gynecol       Date:  2011

4.  Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention: does timing of initiation and compliance matter?

Authors:  Ebony B Carter; Alison G Cahill; Margaret A Olsen; George A Macones; Methodius G Tuuli; Molly J Stout
Journal:  J Perinatol       Date:  2019-06-19       Impact factor: 2.521

5.  Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety.

Authors:  Helen Y How; Baha M Sibai
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

6.  Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth.

Authors:  Alex C Vidaeff; Michael A Belfort
Journal:  Patient Prefer Adherence       Date:  2013-07-11       Impact factor: 2.711

7.  The Effects of Progesterone Therapy on the Gestation Length and Reduction of Neonatal Complications in Patients who had Received Tocolytic Therapy for Acute Phase of Preterm Labor.

Authors:  Marzie Lotfalizadeh; Nayereh Ghomian; Amirreza Reyhani
Journal:  Iran Red Crescent Med J       Date:  2013-10-05       Impact factor: 0.611

8.  The use of progesterone during pregnancy to prevent preterm birth.

Authors:  Eman S Alsulmi; Malikah Alfaraj; Yaser Faden; Noura Al Qahtani
Journal:  Saudi Med J       Date:  2020-04       Impact factor: 1.484

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.